A study published in Urology analyzed the impact of the shortage of bacillus Calmette-Guerin (BCG) on the treatment of non-muscle invasive bladder cancer in the United States. Researchers found that the shortage led to a decrease in the proportion of patients receiving BCG induction therapy and completing the full course of treatment. Instead, there was an increase in the use of other agents like mitomycin C. The shortage also caused an increase in the cost of treating bladder cancer, as demand for alternative agents rose. Researchers are exploring new treatment options like intravesical gemcitabine and docetaxel.
Source link
How the BCG Shortage Has Affected Patients With Bladder Cancer
